menu
    • menu
    [{"orgOrder":0,"company":"Blueberry Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Terbinafine Hydrochloride","moa":"Squalene monooxygenase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Blueberry Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"Blueberry Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Blueberry Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Blueberry Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Terbinafine Hydrochloride","moa":"Squalene monooxygenase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Blueberry Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"Blueberry Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Blueberry Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Blueberry Therapeutics","sponsor":"IQVIA","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"BB2603-10","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Blueberry Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"Blueberry Therapeutics \/ IQVIA","highestDevelopmentStatusID":"8","companyTruncated":"Blueberry Therapeutics \/ IQVIA"}]

    Find Clinical Drug Pipeline Developments & Deals by Blueberry Therapeutics

    Menu

    Blueberry Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Blueberry Therapeutics

                            United Kingdom arrow
                            AAPS
                            Not Confirmed

                            Blueberry Therapeutics

                            United Kingdom arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Terbinafine Hydrochloride

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Blueberry Therapeutics Meets Primary and Secondary Endpoints in Phase 2b Trial in Onychomycosis

                            Details : BB2603, a novel topical terbinafine antifungal product, has met the primary endpoint in the Phase 2b trial (BBTAF202) in patients with onychomycosis, showing superiority over placebo (vehicle) with a high level of statistical significance.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 13, 2023

                            Lead Product(s) : Terbinafine Hydrochloride

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Blueberry Therapeutics

                            United Kingdom arrow
                            AAPS
                            Not Confirmed

                            Blueberry Therapeutics

                            United Kingdom arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Terbinafine Hydrochloride

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Blueberry Therapeutics receives clearance from the FDA to proceed with the clinical investigation of BB2603

                            Details : With the IND in place the company has initiated a Phase IIb international, multicentre double-blinded study.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 28, 2020

                            Lead Product(s) : Terbinafine Hydrochloride

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Blueberry Therapeutics

                            United Kingdom arrow
                            AAPS
                            Not Confirmed

                            Blueberry Therapeutics

                            United Kingdom arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BB2603-10

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : IQVIA

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Trial Involving Treatment of BB2603 in Subjects With Distal Subungual Onychomycosis of the Toenail

                            Details : BB2603-10 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Onychomycosis.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            December 06, 2019

                            Lead Product(s) : BB2603-10

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : IQVIA

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth